Baseline characteristics, procedural and clinical outcomes for the overall DAO population
| MCA–M2 (n=350) | MCA–M3 (n=25) | ACA (n=10) | PCA (n=22) | |
| Baseline characteristics % (n) | ||||
| Age (years), mean±SD | 69.1±13.5 | 66.7±13.9 | 65.9±12.8 | 66.2±14.3 |
| Female | 53.7 (188) | 48 (12) | 30 (3) | 45.5 (10) |
| Hypertension | 75.4 (264) | 72 (18) | 88.9 (8/9) | 77.3 (17) |
| Atrial fibrillation | 35.5 (124/349) | 32 (8) | 33.3 (3/9) | 22.7 (5) |
| Diabetes mellitus | 23.5 (82/349) | 32 (8) | 22.2 (2/9) | 31.8 (7) |
| Previous ICAD | 0.0 (0/349) | 0.0 (0) | 0.0 (0/9) | 0.0 (0) |
| Baseline NIHSS score, median (IQR) | 13(8–18) | 11.5(7–15) | 17.5(12–20) | 14.0(8–16) |
| Pre-morbid mRS 0–1 | 86.7 (300/346) | 95.8 (23/24) | 80 (8) | 90.5 (19/21) |
| IV-tPA use | 52.9 (185) | 48 (12) | 66.7 (6/9) | 50 (11) |
| TLSW to puncture (hours), median (IQR) | 4.1 (2.8–6.4) | 5.2 (2.9–7.8) | 2.6 (2.2–5.0) | 4.7 (3.5–10.7) |
| Time from puncture to device deployment (minutes), median (IQR) | 24.0 (17.0–36.0) | 27.0 (16.5–40.0) | 26.0 (14.0–35.0) | 32.0 (21.0–40.0) |
| Total procedural duration (minutes), mean±SD | 54.3±30.8 | 63.9±27.4 | 49.3±30.3 | 61.4±33.2 |
| Trevo 3×20 mm | 41.7% (144/345) | 80.0% (20/25) | 60.0% (6/10) | 31.8% (7/22) |
| Trevo 4×20 mm | 43.2% (149/345) | 16.0% (4/25) | 40.0% (4/10) | 31.8% (7/22) |
| Trevo 4×30 mm | 11.0% (38/345) | 4.0% (1/25) | 0.0% (0/10) | 31.8% (7/22) |
| Trevo 6×25 mm | 4.1% (14/345) | 0.0% (0/25) | 0.0% (0/10) | 4.6% (1/22) |
| Intermediate catheter | 47.0% (164/349) | 40.0% (10/25) | 70.0% (7/10) | 59.1% (13/22) |
| Intra-arterial lytics | 52.9% (185/350) | 48.0% (12/25) | 66.7% (6/9) | 50.0% (11/22) |
| Number of device passes, median (IQR) | 1(1–2) | 2(1–2) | 1(1–2) | 1(1–2) |
| General anesthesia | 46.6% (163/350) | 36.0% (9/25) | 30 (3) | 54.6 (12) |
| Procedural and clinical outcomes % (n) | ||||
| mTICI 2b–3 (Overall) | 92.3% (323/350) | 92.0% (23/25) | 100% (10) | 100% (22) |
| mTICI 2b–3 (IV tPA use) | 93.0% (172/185) | 83.3% (10/12) | 100% (6/6) | 100% (11/11) |
| mTICI 2b–3 (no IV tPA use) | 91.5% (151/165) | 100% (13/13) | 100% (3/3) | 100% (11/11) |
| mTICI 3 (overall) | 53.7% (188) | 60% (15/25) | 80.0% (8) | 63.6% (14) |
| mTICI 3 (IV tPA use) | 52.4% (97/185) | 41.7% (5/12) | 66.7% (4/6) | 63.6% (7/11) |
| mTICI 3 (No IV tPA use) | 55.2% (91/165) | 76.9% (10/13) | 100.0% (3/3) | 63.6% (7/11) |
| RNI | 44.8% (151/337) | 58.3 (14/24) | 50 (5) | 52.4 (11/21) |
| sICH (overall) | 1.7% (6/350) | 4% (1/25) | 0.0% (0) | 0.0% (0) |
| sICH (IV tPA use) | 0.5% (1/185) | 8.3% (1/12) | 0.0% (0/6) | 0.0% (0/11) |
| sICH (no IV tPA use) | 3.0% (5/165) | 0.0% (0/13) | 0.0% (0/3) | 0.0% (0/11) |
| Vessel perforation | 0.4% (1/247) | 5% (1/20) | 0.0% (0) | 0.0% (0) |
| Emboli to new territory | 2% (7/350) | 8.0% (2/25) | 0.0% (0) | 0.0% (0) |
| 90-day mRS 0–2 | 64.9% (226/348) | 72.0% (18/25) | 50.0% (5) | 59.1% (13) |
| 90- day mRS 0–2 (overall)* | 68.7% (222/323) | 73.9% (17/23) | 62.5% (5) | 57.1% (12/21) |
| 90-day mRS 0–2 (IV tPA use)* | 63.4% (116/183) | 75.0% (9/12) | 50.0% (3/6) | 54.6% (6/11) |
| 90-day mRS 0–2 (no IV tPA use)* | 66.7% (110/165) | 69.2% (9/13) | 33.3% (1/3) | 63.6% (7/11) |
| 90-day mortality | 14.3% (50) | 16.0% (4) | 20.0% (2) | 9.1% (2) |
| 90-day mortality (IV tPA use) | 12.4% (23/185) | 16.7% (2/12) | 16.7% (1/6) | 18.2% (2/11) |
| 90-day mortality (No IV tPA use) | 16.4% (27/165) | 15.4% (2/13) | 33.3% (1/3) | 0.0% (0/11) |
*Subsetted to only pre-stroke mRS 0–2.
ACA, anterior cerebral artery; IV-tPA, intravenous tissue plasminogen activator; MCA, middle cerebral artery; mRS, modified Rankin Scale; mTICI, modified Thrombolysis In Cerebral Infarction; NIHSS, National Institute of Health Stroke Scale; PCA, posterior cerebral artery; RNI, rapid neurological improvement; SAE, serious adverse event; sICH, symptomatic intracerebral hemorrhage; TLSW, time last seen well.